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Abstract
Background: Activation of glucagon-like peptide-1 (GLP-1) receptors improves insulin sensitivity and induces
vasodilatation and diuresis. AC3174 is a peptide analogue with pharmacologic properties similar to the GLP-1
receptor agonist, exenatide. Hypothetically, chronic AC3174 treatment could attenuate salt-induced hypertension,
cardiac morbidity, insulin resistance, and renal dysfunction in Dahl salt-sensitive (DSS) rats.
Methods: DSS rats were fed low salt (LS, 0.3% NaCl) or high salt (HS, 8% NaCl) diets. HS rats were treated with
vehicle, AC3174 (1.7 pmol/kg/min), or GLP-1 (25 pmol/kg/min) for 4 weeks via subcutaneous infusion. Other HS
rats received captopril (150 mg/kg/day) or AC3174 plus captopril.
Results: HS rat survival was improved by all treatments except GLP-1. Systolic blood pressure (SBP) was lower in LS
rats and in GLP-1, AC3174, captopril, or AC3174 plus captopril HS rats than in vehicle HS rats (p < 0.05). AC3174
plus captopril attenuated the deleterious effects of high salt on posterior wall thickness, LV mass, and the ratio of
LV mass to body weight (P ≤ 0.05). In contrast, GLP-1 had no effect on these cardiovascular parameters. All
treatments reduced LV wall stress. GLP-1, AC3174, captopril, or AC3174 plus captopril normalized fasting insulin and
HOMA-IR (P ≤ 0.05). AC3174, captopril, or AC3174 plus captopril improved renal function (P ≤ 0.05). Renal
morphology in HS rats was associated with extensive sclerosis. Monotherapy with AC3174, captopril, or GLP-1
attenuated renal damage. However, AC3174 plus captopril produced the most effective improvement.
Conclusions: Thus, AC3174 had antihypertensive, cardioprotective, insulin-sensitizing, and renoprotective effects in
the DSS hypertensive rat model. Furthermore, AC3174 improved animal survival, an effect not observed with GLP-1.
Background
Cardiovascular disease is the number one cause of death
in the United States.
1 In 2003, ~65 million adults had
diagnosed hypertension, a key risk factor for cardiovas-
cular disease and kidney failure [1,2]. Congestive heart
failure with left ventricular (LV) dysfunction is often
found in patients with hypertension [2-6]. In fact, hyper-
tension is the strongest risk factor for heart failure. The
transition from LV wall hypertrophy compensatory for
abnormal wall stress to overt heart failure has long been
recognized, but the underlying mechanisms remain
poorly understood. However, it is known that during
this transition insulin resistance develops, cardiac glu-
cose uptake down-regulates, angiotensin-converting
enzyme (ACE) levels increase, and the renin-angiotensin
aldosterone system (RAAS) becomes hyperactivated
[2,4,6].
Heart failure and diabetes are intrinsically linked [7].
Diabetes is a risk factor for coronary atherosclerosis
leading to myocardial ischemia and infarction. Diabetes
also causes cardiomyopathy independent of coronary
atherosclerosis. Clinical presentation involves diastolic
dysfunction characterized by abnormal LV relaxation,
reduced systolic function and increased myocardial
reflectivity, and elevated insulin resistance.
Hypertension and diabetes are the two leading causes
of chronic kidney disease [2,8]. Drugs that improve glu-
cose uptake and glucose oxidation have cardioprotective
effects and can attenuate subsequent renal disease [2].
Glucagon-like peptide-1 (GLP-1) is an incretin hormone
with insulinotropic properties that regulates glucose
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insulin resistance and improve glycemic control in
patients with type 2 diabetes. Intravenous infusion of
GLP-1 in patients with acute myocardial infarction for
72 hours after successful angioplasty reportedly
improved cardiac function [10]. Further, in pigs [11] and
dogs [12] GLP-1 improved myocardial glucose-uptake
and metabolism. In Dahl salt-sensitive (DSS) hyperten-
sive rats, GLP-1 attenuated the development of hyper-
tension and cardiac remodeling, reduced renal
proteinuria and albuminuria, and improved functionality
in both organs [13].
Exenatide is a peptide incretin mimetic that shares
many glucoregulatory properties with GLP-1 [14-16].
In vitro, exenatide binds to and activates the known
mammalian GLP-1 receptor. In vivo, exenatide enhances
glucose-dependent insulin secretion, enhances glucose-
dependent suppression of inappropriately high glucagon
secretion, slows gastric emptying, and reduces food
intake. In diabetes models, exenatide can promote b-cell
proliferation and islet neogenesis from precursor cells
[14-17]. In diabetes patients, 30 weeks of exenatide
reduced mean HbA1c ~1% with weight loss, effects that
were sustained out to 3 years in open-label extensions
[15,16]. Exenatide and GLP-1 improved hypertension,
insulin sensitivity, vasodilatation, and renal diuresis in
animal studies [13,17-20]. In both healthy and insulin-
resistant obese men, GLP-1 similarly induced natriuresis
[21]. In an open-label, 82-week study, exenatide reduced
mean diastolic BP and improved lipid profiles [22]. In a
24-week clinical trial, exenatide reduced mean systolic
and diastolic BP in contrast to non-significant BP
changes in the placebo arm [23]. The BP effects of exe-
natide treatment lasting at least 6 months was also
examined in pooled data from 6 trials including 2,171
subjects [24]. Exenatide was associated with significantly
decreased systolic BP compared with placebo or insulin
in patients with elevated BP at baseline, with the great-
est effects observed in subjects with baseline systolic BP
≥ 130 mmHg.
The Dahl salt-sensitive (DSS) rat is a well established
model for salt-induced hypertension and renal failure.
DSS rats fed a high-salt diet (8% NaCl) develop diasto-
lic heart dysfunction characterized by LV hypertrophy
and increased LV myocardial thickness and stiffening
[25-28], with elevated plasma insulin and triglyceride
concentrations coupled with impaired insulin-stimu-
lated glucose transport into cardiac muscle [25,29].
After 7 weeks, kidneys are characterized by decreased
function, increased proteinuria, glomerulosclerosis,
increased adrenomedullin and atrial natriuretic peptide
concentrations compared with salt-resistant rats [30].
By one year of age, DSS rats on low-salt diet develop
glomerulosclerosis and tubulointerstitial fibrosis similar
to the age-related renal changes observed in humans
[31].
The purpose of the present study was to determine
whether hypertension, insulin resistance, and renal dys-
function in DSS rats fed a high-salt diet could be atte-
nuated by the exenatide analogue, AC3174 [32], alone
or in combination with the ACE inhibitor captopril. The
efficacy of AC3174 was also compared to native GLP-1
administered at a dose 12X higher than the AC3174
dose (on a μg/kg/d basis). Compared with exenatide,
AC3174 has a single amino acid substitution (leucine
for methionine at position 14) to eliminate oxidation at
this amino acid and potentially improve peptide stability
[32]. In vitro AC3174 and exenatide have equivalent
potency for displacement of GLP-1 from its receptor
and for receptor activation. In vivo, AC3174 had efficacy
similar to exenatide for decreasing ambient and post-
prandial plasma glucose.
Methods
Male 7-week old Dahl salt-sensitive (DSS) rats [33]
(209 ± 3 g; Harlan Sprague Dawley, Madison, WI) were
fed low salt (0.3% NaCl) or high salt (8% NaCl) chow.
High salt rats were treated for 4 weeks with vehicle or
AC3174 [32] (1.7 pmol/kg/min [10 μg/kg/day]) via sub-
cutaneous infusion (Alzet® pump), with captopril in
drinking water at a dose of 150 mg/kg/day, with
AC3174 plus captopril, or with GLP-1 at a dose of 25
pmol/kg/min (120 μg/kg/day). AC3174 and GLP-1 doses
were selected to provide equivalent plasma exposure
[34]. For implantation of the Alzet osmotic mini-pumps,
rats were anesthetized with ketamine (50-90 mg/kg)
plus xylazine (5-10 mg/kg), a small subcutaneous pocket
was created at the neck nape, the pump was inserted
into the pocket, and the incision closed with wound
clips. All procedures were approved by an Institutional
Animal Care and Use Committee
Systolic blood pressure (BP) was measured by tail cuff
(AD Instruments, Colorado Springs, CO) or telemetry
via an implanted transmitter (DSI transducer, DSI, St.
Paul, MN) placed into the right femoral artery or
abdominal aorta, as instructed by the manufacturer.
Rats were conscious and freely moving in their cages
while blood pressure measurements were collected by
telemetry. Cardiac function was assessed by transthor-
acic echocardiography using a HP Sonos 5500 ultra-
sound system (Davis Medical, San Diego, CA). Body
temperature was maintained by a warm water circulat-
ing heating blanket. After completion of the observation
period, animals were euthanized by overdosing with iso-
flurane and exsanguination was performed by cardiac
puncture.
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(HOMA-IR) index was calculated from fasting plasma
glucose and insulin concentrations according to the
equation (insulin*glucose)/22.5. A bolus intraperitoneal
injection of 2 g glucose/kg body weight was adminis-
tered for the glucose tolerance test at week 5. Rats were
fasted overnight for at least 6 hours for fasting measure-
ments. Blood glucose samples were obtained via tail
vein.
Renal function was evaluated by measuring serum and
urinary creatinine concentrations and by calculating
renal creatinine clearance rates according to the equa-
tion: Clearance rate (ml/min) = (urine creatinine concen-
tration*urine volume)/serum creatinine concentration/
time period.
Tissue samples were fixed via intracardiac perfusion
with 10% buffered formalin and paraffin-embedded
overnight in a Miles VIP Tissue Processor. Serial 8
micron thick sections were cut with a Leitz microtome,
stained with a routine Harris hematoxylin and eosin
stain or trichrome blue, photographed using an Olym-
pus BH2 Fluorescent microscope with a SpotRT digital
camera (Olympus, Temecula, CA), and analyzed using
Image-Pro Plus 4.1 software (DataCell Ltd, North
Chelmsford, MA).
Students’ t-tests, one-way ANOVA followed by Bon-
ferroni multiple comparison tests, or two-way ANOVA
followed by Bonferroni multiple comparison tests were
used to test treatment group differences at defined time
points. Repeated measures analyses and Dunnett’st e s t s
were used to compare treatment groups to the high salt
group over time. Animal survival was evaluated using
Kaplan-Meier survival curves. Data are presented as
mean ± SEM.
Results
General model characteristics are shown in figure 1.
After 4 weeks on a high salt diet, systolic BP increased
60%. In contrast, systolic BP in rats fed a low salt diet
increased only 17%. Mean arterial pressure (MAP)
remained relatively unchanged in low salt rats, but
increased by 73% in high salt rats. Pulse pressure
increased by 15% and 68%, respectively. Body weight
gain was similar. Treatment with AC3174, captopril,
GLP-1, or the combination of AC3174 plus captopril
reduced systolic BP compared with high salt diet alone
(P ≤ 0.05), but had no effect on body weight gain.
Further, the development of cardiometabolic and renal
disease in high salt rats had a dramatic effect on survi-
val, with 50% mortality before week 5 and zero survival
by week 7. In contrast, none of the low salt rats died
during the 8-week observation period. AC3174, capto-
pril, and AC3174 plus captopril all lengthened survival
among high salt rats (P ≤ 0.05), with AC3174 plus
captopril being the most beneficial. The predicted 50%
survival weeks were 5.5 (high salt), 5.7 (GLP-1), 7.8
(captopril), 9.4 (AC3174), and 10.4 (AC3174 plus
captopril).
The deleterious cardiovascular effects of a high salt
diet were ameliorated to different degrees by the tested
treatments (figure 2). Systolic BP was significantly lower
in low salt rats (132 ± 14 mmHg) than in high salt rats
(209 ± 7 mmHg; P ≤ 0.05). AC3174 (155 ± 17 mmHg),
captopril (165 ± 16 mmHg), GLP-1 (178 ± 14 mmHg),
and AC3174 plus captopril (163 ± 16 mmHg) all signifi-
cantly reduced systolic BP versus high-salt rats (P ≤
0.05), with GLP-1 having the least effect. In concert
with worsening hypertension, LV mass and ventricular
wall thickness both increased compared with low salt
rats. AC3174 plus captopril attenuated the effects of
high salt on posterior wall thickness, LV mass, and the
ratio of LV mass to total body weight (P ≤ 0.05). How-
e v e r ,G L P - 1t r e a t m e n th a dn oe f f e c t .T h er a t i oo fL V
mass to total body weight was also reduced by a low
salt diet, AC3174 monotherapy, or captopril monother-
apy compared with a high salt diet alone (P ≤ 0.05). All
treatments reduced LV wall stress: 22% (low salt), 30%
(AC3174), 20% (captopril), 28% (combination), and 27%
(GLP-1) compared with high salt alone (P ≤ 0.05).
There were no effects on fasting glucose in this nor-
moglycemic rat model (figure 3). However, compared
with low salt rats, fasting insulin and HOMA-IR were
significantly increased by 2.3-fold in high salt rats (P ≤
0.05), indicating insulin resistance. GLP-1, AC3174, cap-
topril, or AC3174 plus captopril normalized fasting
insulin and HOMA-IR (P ≤ 0.05).
Postprandial glucose concentrations remained elevated
in high salt DSS rats at 30 and 60 minutes post-glucose
load (figure 4). This was in sharp contrast with the low
salt, AC3174, or AC3174 plus captopril groups, where
indistinguishable and more rapid normalization
occurred. GLP-1 was less effective. Postprandial insulin
had a more variable treatment response. Insulin levels in
rats fed high salt alone, GLP-1, or captopril monother-
apy were similarly blunted after the glucose bolus. How-
ever, in the low salt, AC3174 monotherapy, and
combination groups, postprandial insulin rapidly
increased to levels ~2.4-fold higher than in the high salt
group by 15 minutes post-bolus and remained generally
elevated until 60 minutes post-bolus.
AC3174, captopril, or the combination attenuated ele-
vated serum creatinine and improved creatinine clear-
ance rates compared with a high salt diet alone (P ≤
0.05; figure 5). GLP-1 improved creatinine clearance
rates. Renal morphology in low salt rats (figure 6) was
comparable to normal rats (data not shown) with no
inflammation or fibrosis and minimal sclerosis (sclerosis
score 0.67 ± 0.19). In contrast, a high salt diet was
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moderate-to-severe sclerosis (sclerosis score 3.10 ± 0.18;
P ≤ 0.05 versus low salt). AC3174 (sclerosis score 2.33 ±
0.41), captopril (sclerosis score 2.33 ± 0.29), or GLP-1
(sclerosis score 2.00 ± 0.45) each visibly attenuated renal
damage to a similar extent compared with a high salt
diet. However, the combination of AC3174 and capto-
pril produced the most improvement (sclerosis score
1.50 ± 0.20; p ≤ 0.05 versus high salt; p > 0.05 versus
low salt).
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Figure 1 Development of hypertension in the DSS rat over 4 or 5 weeks of high (8% NaCl) or low (0.3% NaCl) salt diet.( A )S y s t o l i c
blood pressure measured by tail cuff. No difference among groups at baseline. At week 4, systolic blood pressure was significantly lower in all
groups compared with a high salt diet alone (P ≤ 0.05). The pooled-over-time mean of the low salt group was significantly different from the
high salt group (p < 0.003) (B) Arterial blood pressure measured by implanted transmitter. *P ≤ 0.05 versus high salt diet alone. (C) Pulse
pressure measured by implanted transmitter. *P ≤ 0.05 versus high salt diet alone. (D) Change in body weight. (E) Kaplan-Meier survival curves
followed for 8 weeks. N = 7 to 10 rats per group (N = 3 to 8 for telemetry data). Mean ± SEM.
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Figure 2 Cardiovascular changes after 4 weeks of treatment demonstrated beneficial effects of AC3174. (A) Systolic blood pressure. P =
0.0226 for one-way ANOVA. The pooled-over-time means of the low salt and AC3174 groups were significantly different from the high salt
group (P ≤ 0.05). (B) Posterior left ventricular wall thickness. P = 0.0030 for one-way ANOVA. The pooled-over-time mean of the low salt group
was significantly different from the high salt group (P ≤ 0.05). (C) Left ventricular heart mass. P = 0.0002 for one-way ANOVA. The pooled-over-
time means of the low salt and AC3174 plus captopril groups were significantly different from the high salt group (P ≤ 0.05). (D) Left ventricular
heart mass as a percentage of total body weight. P < 0.0001 for one-way ANOVA. The pooled-over-time means for all treatment groups, except
GLP-1, were significantly different from the high salt group (P ≤ 0.05). (E) Left ventricular heart wall stress. P = 0.0512 for one-way ANOVA. The
pooled-over-time means of the AC3174 and AC3174 plus captopril groups were significantly different from the high salt group (P ≤ 0.05). There
were 10 rats per group at beginning of treatment. N = 3 to 10 rats per group at end of treatment actually shown. *P < 0.05 versus high salt diet
alone. Mean ± SEM.
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Treatment of DSS rats fed a high salt diet with the exe-
natide analogue AC3174, captopril, or AC3174 plus
captopril markedly attenuated the development of
hypertension and cardiomyopathy. The overall efficacy
of AC3174 was comparable to captopril. However, the
effect of AC3174 was additive with captopril in
normalizing LV mass. Thus, AC3174 had cardiovascular
benefits beyond those achieved via ACE inhibition
alone, either by enhancing captopril effectiveness, or
more likely, by an independent mechanism. One possi-
ble mechanism for the additive effects of AC3174 and
captopril could be increased concentrations of circulat-
ing angiotensin(1-7) [35]. In spontaneously hypertensive
rats, angiotensin(1-7) was the only component of the
renin-angiotensin system that was elevated compared
with normotensive rats. In addition, chronic ACE inhibi-
tion resulted in elevated angiotensin(1-7) levels in both
hyper- and normotensive rats.
Overall, AC3174 monotherapy or AC3174 plus capto-
pril was more efficacious than GLP-1. In a previously
reported study, GLP-1 infusion prevented cardiac hyper-
trophy, reduced cardiac fibrosis, lowered MAP, and par-
tially restored endothelial fu n c t i o ni ni s o l a t e da o r t i c
rings from high salt DSS rats [13]. In salt-sensitive
obese diabetic mice, exenatide attenuated the develop-
ment of hypertension and body weight gain, and
increased urinary sodium excretion [20]. Additionally, in
a rat model of metabolic syndrome, exenatide reversed
corticosterone-induced elevations in BP independent
from weight change [19]. Exenatide reduced corticoster-
one-induced hypertension by 86%. Finally, in a pig
model of acute myocardial infarction, exenatide treat-
ment before reperfusion improved cardiac function,
reduced infarct size, and decreased myocyte apoptosis
within the ischemic infarct site [36]. Taken together,
these data suggest that GLP-1 receptor agonists such as
exenatide and AC3174 have potential as therapeutic
agents for preventing and attenuating the development
of hypertension and cardiac hypertrophy.
DSS rats fed a high salt diet rapidly developed pro-
found hypertension, LV hypertrophy, insulin resistance,
and renal pathology leading to early-onset mortality
from hypertension-induced stroke, with 50% mortality
before week 5 and zero survival by week 7. In contrast,
none of the low salt DSS rats died during the 8 week
observation period. AC3174, captopril, and AC3174 plus
captopril all lengthened survival among high salt DSS
rats, with the combination being the most effective.
Previous data have demonstrated that although acute
exposure to exenatide decreases food intake in the
short-term, this effect disappears after a week with
chronic exenatide exposure [37]. Thus, rats treated with
the exenatide analogue AC3174 were exposed to equiva-
lent salt content from food intake as other treatment
groups. In contrast, GLP-1 did not improve survival.
This resulted in fewer GLP-1 animals being available for
end-of-study analyses.
DSS rats fed a high salt diet develop cardiac dysfunc-
tion leading to failure characterized by LV hypertrophy,
increased LV wall stress, and LV fibrosis [13,26,28]. DSS
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Figure 3 Beneficial effects of AC3174 on fasting glycemic
control after 4 weeks of treatment. (A) Fasting serum glucose
concentrations. No significant differences among groups. (B) Fasting
serum insulin concentrations. P = 0.0020 for one-way ANOVA. The
pooled-over-time means of the low salt, AC3174, and captopril
groups were significantly different from the high salt group (P ≤
0.05). (C) HOMA. P = 0.0014 for one-way ANOVA. The pooled-over-
time means for all treatment groups except GLP-1 were significantly
different from the high salt group (P ≤ 0.05).
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hypertension antecedent to compensatory LV hypertro-
phy with LV relaxation abnormalities by 13 weeks of
age [26]. By 17 weeks of age, there was further progres-
sion of LV hypertrophy combined with fibrosis and
myocardial stiffening. Overt diastolic heart failure,
increased LV filling pressure, and pulmonary congestion
occurred by approximately 20 weeks of age; followed
shortly by death [26,28].
There is a strong correlation between insulin-resis-
tance and hypertension in humans [38-40]. Insulin resis-
tance has been linked to cardiac hypertrophy and
fibrosis, endothelial dysfunction, and renal glomerulo-
sclerosis. Hyperinsulinemia may contribute to the devel-
opment of hypertension by promoting endothelial
dysfunction and stimulating renal tubule reabsorption of
sodium [39]. Conversely, increasing insulin sensitivity is
associated with increased cardioprotection, normalized
endothelial function, and reduced MAP [13,25,40].
The DSS rat model of hypertension exhibits insulin-
resistance exacerbated by salt intake and age [40]. One
mechanism by which high salt might precipitate insulin
resistance is through its ability to enhance an oxidative
stress-induced inflammatory response that disrupts the
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Figure 4 Beneficial effects of AC3174 on postprandial glycemic control after 4 weeks of treatment. (A) Serum glucose concentrations
after an intraperitoneal bolus of glucose. No significant difference between the GLP-1 and high salt alone groups. At 30 min post-bolus, low salt,
AC3174, GLP-1, and combination AC3174 plus captopril treatment significantly lowered glucose concentrations compared with high salt diet
alone (P ≤ 0.05). At 60 min post-bolus, low salt, AC3174, and AC3174 plus captopril significantly lowered glucose concentrations compared with
high salt diet alone (P ≤ 0.05). At 120 min post-bolus, AC3174 and AC3174 plus captopril significantly lowered glucose concentrations compared
with high salt diet alone (P ≤ 0.05). No data were collected from the captopril group. (B) Serum insulin concentrations after an intraperitoneal
bolus of glucose. A high salt diet lowered insulin concentrations at all post-bolus time points compared with a low salt diet (P ≤ 0.05). No
significant difference between the GLP-1 and high salt groups. Captopril significantly lowered insulin concentrations at 30, 60, and 120 min post-
bolus compared with a high salt diet (P ≤ 0.05). Treatment with AC3174 (alone or with captopril) significantly raised insulin concentrations at 15
and 120 min post-bolus compared with high salt diet alone (p < 0.05). *P ≤ 0.05 versus high salt diet. N = 3 to 14 rats per group. Mean ± SEM.
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Figure 5 Beneficial effects of AC3174 on renal function after 4 weeks of treatment. (A) Serum creatinine concentrations. P = 0.0003 for
one-way ANOVA. (B) Glomerular filtration rate measured by creatinine clearance. P = 0.0001 for one-way ANOVA. *P ≤ 0.05 versus high salt diet.
N = 3 to 14 rats per group. Mean ± SEM.
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Page 7 of 10insulin signaling pathway [41]. Fujii et al. [25] reported
that fatty acid oxidation and insulin-stimulated glucose
uptake were impaired in high salt DSS rats with cardiac
hypertrophy. Further, glucose uptake was maximally sti-
mulated under basal conditions in the hypertrophied
heart, with no residual capacity to increase glucose
uptake in response to insulin administration. The new
findings reported here are that treatment of high salt
DSS rats with AC3174, captopril, or the combination
reduced fasting insulin and insulin resistance with no
effect on fasting glucose, similar to GLP-1. Chronic
treatment with exenatide or GLP-1 is associated with
increased insulin sensitivity in preclinical models
[17,42]. Further, these changes were at least as great as
the change associated with metformin, TZDs, SFUs, or
insulin therapy. Given the correlation between insulin
resistance, hyperinsulinemia, and hypertension leading
to more serious cardiovascular disease [39], these data
lend further support for the potential of AC3174 ther-
apy in this setting. After a glucose load (postprandial
state), ambient glucose concentrations remained ele-
vated for an extended period of time in high salt DSS
rats and to a slightly lesser extent in GLP-1 treated high
salt rats. This was in sharp contrast to all other treat-
ment groups where more rapid normalization of glucose
levels occurred. The insulin response to a glucose load
was muted in high salt rats receiving vehicle or
captopril. In contrast, the insulin response in high salt
rats treated with AC3174 monotherapy or AC3174 plus
captopril was 3-fold more vigorous within 15 minutes
post-glucose load. These data point to the ability of a
GLP-1 receptor agonist to independently stimulate an
insulinotropic response to glucose loading in the context
of advanced cardiac and renal disease.
The RAAS plays a significant role in the emergence of
LV dysfunction by instigating myocardial fibrosis, volume
overload, vasoconstriction, and cardiovascular tissue
inflammation [6]. After 7 weeks on a high salt diet, DSS
rat kidneys are characterized by decreased function,
increased proteinuria, glomerulosclerosis, increased adre-
nomedullin and atrial natriuretic peptide concentrations
compared with salt-resistant rats [30]. DSS rats on a high
salt diet develop a renal pathology resembling that
observed in patients with diabetic nephropathy and
hypertensive-induced end stage renal disease [13,30,43].
Supporting these findings is the demonstrated ability of
ACE inhibitors, ARBs, and aldosterone antagonists to
delay renal disease progression in this model [28,43].
Captopril administration to male high salt DSS rats pre-
vented a further increase in systolic BP, but had no effect
on plasma sodium concentration, plasma osmolality, or
hematocrit [44]. Long-term captopril infusion slowed the
expected rise in systolic BP, increased urinary protein
excretion, and slowed renal glomerular sclerosis [43].
Figure 6 Renal histopathology in DSS rats after 4 weeks of treatment demonstrated beneficial effects of AC3174. (A) Low salt diet
exhibiting normal-to-mild scattered sclerosis. (B) High salt diet showing diffuse severe sclerosis. (C) AC3174 treatment on a background of a high
salt diet displaying scattered moderate sclerosis. (D) Captopril treatment on a background of a high salt diet showing diffuse mild sclerosis. (E)
AC3174 plus captopril treatment on a background of a high salt diet showing scattered mild sclerosis. (F) GLP-1 treatment on a background of a
high salt diet exhibiting scattered mild sclerosis. N = 5 to 12 rats per group.
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Page 8 of 10Under the conditions used in the study reported here,
AC3174, captopril, or the combination improved glo-
merular filtration rate more than GLP-1 in DSS rats fed
a high salt diet. Yu et al. [13] reported that intravenous
infusion of GLP-1 into DSS rats fed a high salt diet for
2 weeks attenuated the development of hypertension,
renal proteinuria, and renal albuminuria. GLP-1 also
reduced glomerulosclerosis, renal tubule necrosis, and
the degree of renal interstitial fibrosis in the outer
medulla. Taken together, these data suggest that GLP-1
receptor agonists can promote renal salt and water
excretion by inhibiting tubular reabsorption of sodium,
a mechanism contributing to the antihypertensive effects
in this model.
In the kidneys of high salt DSS rats, more than 75% of
the area of the glomerular capillaries can be filled with
matrix material, indicating a high degree of glomerular
injury [13]. This pathology is accompanied by a marked
necrosis of renal tubules and formation of protein casts
in the outer medulla. In one study, GLP-1 normalized
renal morphology to a degree comparable to kidneys in
low salt DSS rats [13]. As reported here, the morphol-
ogy of high salt DSS rat kidneys showed a high degree
of sclerosis that was improved comparably by AC3174
or captopril monotherapy. Notably, combination treat-
ment with AC3174 and captopril further improved renal
sclerosis and this effect was better than that induced by
GLP-1 monotherapy. Since the anti-hypertensive effects
were comparable among AC3174, captopril, and
AC3174 plus captopril, the renal histopathological
improvements from AC3174 plus captopril suggest an
additional direct effect of AC3174 on the heart and kid-
ney combined with the possibility of indirect effects
from lowered BP.
Conclusions
DSS rats fed a high salt diet rapidly developed profound
hypertension, cardiac hypertrophy, insulin resistance,
and renal pathology leading to early-onset mortality.
AC3174, captopril, and AC3174 plus captopril all
lengthened survival, in contrast to GLP-1. AC3174 had
anti-hypertensive, insulin-sensitizing, and renoprotective
effects. The overall efficacy of AC3174 was comparable
to that of captopril and better than GLP-1. However,
the effects of AC3174 were additive with captopril in
reducing LV mass and improving renal morphology, and
AC3174 independently stimulated an insulinotropic
response to glucose loading in the context of advanced
cardiac and renal disease. These data suggest further
clinical investigations of GLP-1 receptor agonists in the
treatment of cardiorenal syndrome and hypertension are
warranted.
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